Physician profile
Shilpkumar Arora
NPI 1699194365
$7,619.85
in general payments reported to CMS, 2019-2025
31 companies · $2,209 in 2025
The $2,209 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $174 · 2020: $291 · 2021: $618 · 2022: $1,618 · 2023: $1,754 · 2024: $955 · 2025: $2,209.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,640 · Travel and Lodging: $1,128 · Consulting Fee: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,639.92 |
| Travel and Lodging | $1,127.92 |
| Consulting Fee | $150.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $2,404.43 | 2022-2025 | Mo.Ma Ultra, Corevalve Evolut R, Hawkone |
| Abbott Laboratories | $1,329.25 | 2020-2025 | Cardiomems, Jeti All In One Non-Sterile Kit, Jeti Peripheral Catheter |
| Abiomed | $783.23 | 2019-2025 | Impella |
| Amgen INC. | $516.91 | 2019-2025 | Repatha, Repatha |
| Philips North America LLC | $426.80 | 2023 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $243.11 | 2019-2025 | Lifevest |
| Siemens Medical Solutions USA, INC. | $239.27 | 2022 | |
| Janssen Pharmaceuticals, INC | $200.20 | 2019-2024 | Xarelto |
| Pfizer INC. | $182.29 | 2019-2022 | |
| Boston Scientific Corporation | $179.41 | 2023-2025 | Comet, Ranger, Watchman |
| Novartis Pharmaceuticals Corporation | $139.41 | 2023-2025 | |
| Atricure, INC. | $133.66 | 2024-2025 | Synergy Ablation System |
| Inari Medical, INC. | $124.97 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Cardiovascular Systems INC. | $120.20 | 2022 | |
| Heartflow, INC. | $113.08 | 2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Recor Medical INC | $78.18 | 2024 | Paradise Renal Denervation System |
| Lantheus Medical Imaging, INC. | $63.80 | 2019-2021 | |
| Genzyme Corporation | $58.29 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $46.04 | 2021-2024 | Eliquis |
| W. L. Gore & Associates, INC. | $40.59 | 2022-2023 | Gore Cardioform Septal Occluder |
| Edwards Lifesciences Corporation | $25.85 | 2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Astrazeneca Pharmaceuticals LP | $25.24 | 2020-2025 | Farxiga |
| Shockwave Medical, INC | $23.71 | 2025 | |
| Chiesi USA, INC. | $18.48 | 2024 | Kengreal, Cleviprex |
| Sanofi-Aventis U.S. LLC | $17.92 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.64 | 2021 | |
| Alexion Pharmaceuticals, INC. | $16.00 | 2021 | |
| Lundbeck LLC | $15.44 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $12.79 | 2022 | |
| Esperion Therapeutics, INC. | $12.42 | 2020 | |
| Portola Pharmaceuticals, LLC | $11.24 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shilpkumar Arora listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.